アルコール業界が依存するヘビードリンカー
ビールや蒸留酒の広告には大抵、「責任を持って飲みましょう」という注意書きが入っている。それでもアルコール業界は、公衆衛生当局が安全だとする量以上に飲む人たちに依存している。
株式調査会社バーンスタインが2023年に発表した分析によると、米国のアルコール販売量の推定90%は成人の5分の1が消費している。
Most ads for liquor or beer include a reminder to 'drink responsibly.' Still, the alcohol industry depends on people who drink more than public-health officials say is safe.
A fifth of adults account for an estimated 90% of alcohol sales volumes in the U.S., according to an analysis published in 2023 by equity research firm Bernstein.
'Heavier drinkers are obviously where the money is,' said Philip Cook, a professor emeritus at Duke University whose 2007 book, 'Paying the Tab,' was among the scientific studies analyzed by Bernstein.
That dependence has become a greater risk to companies as the U.S. government considers putting cancer warnings on alcohol packaging and lowering the recommended limit of drinks a day that people can safely consume.
The industry's sales are declining because of consumer health concerns, expanding legalization of cannabis, the use of GLP-1 drugs such as Ozempic and a generational shift toward less alcohol consumption. That leaves beer, wine and spirits companies more reliant on people like Kevin Turner.
'People know alcohol is bad for you, that it can be addictive. People understand that,' said Turner, 39 years old, of Orlando, Fla. 'It is poison. It is delicious poison, but it is absolutely poison.'
On weeknights, Turner enjoys a couple of glasses of liquor from his home bar, which includes a dozen Scotches, as well as other whiskeys, bourbons, rums, gins and liqueurs. On weekend evenings, he often meets up with friends at a local bar for three or four beers. Turner, a former smoker, said he is confident he could stop drinking if he wanted to, but a cancer warning label or a revision to the federal dietary guidelines wouldn't immediately change his habits.
For nearly three decades, the guidelines have said it is safe for men to have a maximum of two drinks a day and for women to have one. A standard drink measure in the U.S. is equivalent to 12 ounces of beer, five ounces of wine or 1.5 ounces of distilled spirits.
Alcohol-industry veterans say they are aware of the loyal customers but don't market to them.
'In any category, especially in alcohol, the industry is very concerned about overconsumption,' said Ann Mukherjee, the former North America chief at Pernod Ricard who introduced an Absolut Vodka marketing campaign addressing the role of alcohol in sexual assault.
The alcohol industry, she said, would prefer to 'be less reliant on just a small group driving a majority of consumption. They don't think this is healthy for their own business, sustainability of the category, and for their own consumers.'
Today, federal rules require alcohol labels with warnings about drunken driving and drinking during pregnancy, as well as a general warning that alcohol 'may cause health problems.' Beer, wine and spirits makers have corporate responsibility programs aimed at curbing underage drinking and impaired driving. And they try to avoid being seen as encouraging heavy drinking. Industry insiders say they spend more time worrying about how to attract new customers than retaining their old ones.
It is hard to pinpoint how much people drink because people often underreport their own consumption. According to survey data from the Centers for Disease Control and Prevention, 6% of American adults say they drink enough to meet the agency's definition of heavy drinking: at least 15 drinks a week for men and eight drinks for women. Bernstein's 2023 analysis put the figure much higher, finding that people who consume more than 14 drinks a week represent as much as 20% of adults in the U.S.
Federal guidelines on alcohol consumption could change this year in an update by the Agriculture and Health and Human Services departments. A report issued this month to inform the new guidelines found that for both men and women, one drink a day increases the risk of death from alcohol-related illnesses and injuries. The link between alcohol consumption and cancer risk has been established for at least seven types of cancer, including breast, colorectum, esophagus, liver, mouth, throat and voice box, according to the surgeon general. Alcohol consumption is the third leading preventable cause of cancer in the U.S., after tobacco and obesity.
The alcohol industry generally acknowledges that heavy drinking increases the risk for several types of cancer, and the industry acknowledges that some studies have linked moderate drinking with increased breast-cancer risk. But industry groups also say that alcohol consumed in moderation can be part of a healthy lifestyle for some people. Industry lobbyists are fighting to prevent any changes to the federal guidelines, arguing that the risks are already known and that the government should take into consideration a recent report showing that moderate drinking lowers mortality rates.
The discussion around the cancer risks of alcohol adds pressure to an already struggling industry.
Shares of Constellation Brands plummeted this month after the company reported lower-than-expected beer sales and a $2.25 billion write-down on its wine and spirits business. The company—which makes Modelo Especial beer, Meiomi wine and Casa Noble tequila—lowered its sales and profit forecasts.
Spirits maker Diageo has warned that it is facing weak consumer demand. And distillers in Kentucky are feeling pain as America's bourbon boom comes to an end, leaving them with a glut of barrels. Jack Daniel's maker Brown-Forman last week said it would cut about 12% of its workforce, or roughly 648 jobs.
These trends could make the alcohol industry's reliance on its most ardent fans more acute—and more fraught.
Tara Prinzivalli, 45, who lives in Staten Island, N.Y., drinks two or three glasses of wine nearly every evening at home or with her neighbors across the street. Prinzivalli, who prefers pinot grigio and Malbec, works as a radiation therapist treating cancer patients. She said a warning label about links between cancer and alcohol wouldn't prompt her to cut down.
'Cancer is not something I think about with wine,' Prinzivalli said. 'Maybe I love it too much or am just naive.'
Write to Laura Cooper at laura.cooper@wsj.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
Yahoo
6 hours ago
- Yahoo
Common Childhood Virus Linked to Alzheimer's Development in Old Age
A study published 30 years ago is striking up new conversation about the potential connection between the common cold sore and Alzheimer's disease. Published in The Lancet in 1997, researchers compared DNA extracted from the brains of elderly people with and without Alzheimer's, and in some of them, found herpes simplex virus 1 (HSV-1)—an infection often contracted in childhood—dormant in the nerves. Ultimately, researchers predicted that those with HSV-1 and a specific gene, called the ApoE-e4 gene, had a higher risk of developing Alzheimer's. Meet the Experts: David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston, Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System; and Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. Study co-author Ruth Itzhaki, Ph.D., summarized her team's findings in a recent article for The Conversation and noted that, over the years, additional work has surfaced to support hers. But what does it all mean, exactly? If a cold sore pops up, should you be concerned about dementia? We reached out to experts who explained everything. 'HSV-1 is a common virus to which almost everyone is exposed early in life,' says David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston. 'It is best known for causing cold sores and is closely related to chicken pox and mononucleosis.' What these viruses have in common is that they are neurotropic, meaning they linger in the nervous system long after the initial illness, explains Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System, and can be reactivated by stress or lowered immunity. That's how, for instance, chicken pox can manifest later in life as shingles, adds Dr. Hunter. The virus's ability to infiltrate the nerves is believed to get it past the blood-brain barrier, a membrane that shields the organ from infection via the bloodstream. Thanks to that entry point, Dr. Hunter says, HSV-1 is the most common cause of viral brain inflammation in the United States. 'There is no vaccine for HSV and almost everyone will get it by adulthood,' Dr. Hunter adds. Cold sores are a mild case of it, and symptoms can be treated with antiviral drugs. Dormant HSV-1 may be reactivated by illness and reach the brain, explains Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. This can trigger brain inflammation over time, known as herpes encephalitis,and in people with genetic risk factors, like the ApoE-4 gene, contribute to Alzheimer's development, he adds. 'We don't entirely know why ApoE-4 is a risk factor for Alzheimer's,' adds Dr. Hunter. 'The link to HSV could be that ApoE-4 impacts the blood-brain barrier and makes it easier for HSV to enter.' And the inflammation caused by that entry may heighten Alzheimer's risk. 'It is now universally accepted that inflammation in the brain is a key step in the development of Alzheimer's,' Dr. Hunter reiterates. In the three decades since the original study, doctors and researchers have learned much more about Alzheimer's disease and its connection to viral inflammation. For instance, several studies have found that being immunized for any disease (like COVID-19 or the flu) reduces Alzheimer's risk, says Dr. Hunter. 'Several other studies have shown that reducing inflammation in the brain helps prevent Alzheimer's,' he adds. Santos concurs. 'Since 1996, additional studies have found HSV-1 DNA in the brains of individuals with Alzheimer's. Lab studies have also shown that HSV-1 infection can trigger the buildup of amyloid-beta and tau—proteins strongly associated with Alzheimer's pathology,' he explains. However, there are a few disclaimers to note. Firstly, the posed risk is associated with people who contract HSV-1 in early life, giving it time to progressively cause inflammation. The risk may be lower in adults, says Santos. 'That said, if someone has other risk factors (like a weakened immune system or APOE-e4), adult-onset HSV-1 could still have long-term consequences,' he adds. Still, neurotropic viruses are extremely common, Dr. Yancey reiterates. 'This makes it difficult to tease out whether they are causing neurologic problems or are simply common in the general population, including people with neurologic problems,' she adds. In other words, because most people end up with HSV-1 doesn't necessarily mean that most people will get Alzheimer's. 'Most cold sores aren't a cause for concern,' Santos adds. 'They're common and usually well-controlled by the immune system. But for people with frequent outbreaks, weakened immunity, or APOE-e4, it may be worth discussing with a healthcare provider. The concern is not a single cold sore, but long-term viral activity in the brain.' More research, including long-term studies, is needed to make any solid associations, Santos and Dr. Yancey conclude. 'The current data is based on population-level surveys. There is no way to predict on an individual patient's level whether this has a meaningful impact,' says Dr. Yancey. Future research will, hopefully, at least help experts understand how antiviral treatment affects Alzheimer's risk, as well as identify better ways to detect when HSV-1 is active in the brain. 'The hope is that understanding how infections contribute to Alzheimer's will open up new ways to prevent or treat it—especially before symptoms start,' says Santos. Being vaccinated, exercising, engaging in mental stimulation, and maintaining a heart-healthy diet are all known ways to lower dementia risk, our experts say. Avoiding smoking or nicotine use of any kind can also 'drastically' reduce the risk, says Dr. Yancey. All of these habits and choices work together to support both immune and brain health. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
6 hours ago
- Yahoo
Nigerian Medical Advocates Rally on Capitol Hill for J-1 Visa Fix and Immigrant Physician Bill
WASHINGTON, June 9, 2025 /PRNewswire/ -- The Nigerian Physician Advocacy Group (NPAG), will host a two-day Advocacy & Lobby Day on June 10–11, 2025, on Capitol Hill to highlight the vital role Nigerian American physicians play in filling healthcare shortages and call on Congress to remove systemic barriers to their continued service by reforming the J-1 visa program and passing the Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201), also known as the "Doctors in Our Borders" bill. The NPAG delegation will be led by Dr. Susan Edionwe, Nigerian American physicians, health advocates, and community leaders. This initiative comes amid targets on international students at U.S. universities and growing concerns over the increasing number of J-1 visa denials, which prevent qualified international medical graduates (IMGs)—especially Nigerian-trained physicians—from contributing their expertise to underserved and rural communities across the United States. Nigerian American physicians have played an important role in filling healthcare shortages in the United States and the advancement of our country's healthcare system is dependent on the removal of systemic barriers to their continued service. "Doctors from Nigeria and across Africa have long served in America's most vulnerable communities—from inner cities to remote rural counties," said Dr. Susan Edionwe. "Fixing the J-1 process and passing H.R. 1201 is essential to ensuring our communities have access to the care they desperately need." "NPAG encourages policymakers, allies, and the media to recognize the indispensable contribution of Nigerian and African-trained doctors to the American healthcare system—and to take legislative action to protect and expand their role in advancing national health equity," said Dr. Susan Edionwe. About Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201): H.R. 1201 a bipartisan bill, would reauthorize and expand the Conrad 30 waiver program, which allows J-1 physicians to remain in the U.S. after residency by serving in Health Professional Shortage Areas (HPSAs). The legislation provides states with greater flexibility, increases waiver caps, and reduces processing delays—ensuring medically underserved communities continue receiving essential care. About NPAG: The Nigerian Physician Advocacy Group is a national coalition of Nigerian American doctors and advocates committed to advancing health equity, shaping inclusive immigration policy, and addressing physician workforce challenges in the United States. View original content to download multimedia: SOURCE Nigerian Physician Advocacy Group (NPAG)